Drugs for metabolic diseases, vaccines, and cancer therapies feature among new product launches this year that could top $1 ...

Researchers developed an assay kit for TAT, then conducted a retrospective analysis to determine its ability to predict VTE in patients with cervical cancer.

Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, today announced the release of the ...

By the end of March, the regulator could clear a highly anticipated pain drug from Vertex and a heart drug that’s critical to ...

To identify this year’s Drugs to Watch 2025 list, Clarivate drew from expertise from over 160 Clarivate analysts covering ...

Some other medicines that are slated to become blockbusters in the near future include GSK’s vaccine candidate GSK-3536819 ...

2009 approval highlights One such product that was approved by CBER, but not CDER, was recombinant human antithrombin (ATryn; GTC Biotherapeutics) for the treatment of hereditary antithrombin ...

First up is Alnylam-partnered RNAi candidate fitusiran, an antithrombin-targeting agent in development as a treatment for haemophilia A and B with as few as six injections per year, making it a ...

Labor can increase the risk for compromised oxygenation in the fetus. Uterine contractions produce transient decreases in blood flow to the placenta, which can lead to interruptions in gas ...

Hemophilia News Today compiled a summary of the 10 most read hemophilia stories of 2024, with links to the individual items.

Advances in science and technology have allowed researchers to gain a better understanding of the pathophysiology leading to long-term neurologic damage in newborns. Intrapartum events are now ...

004000.KS LOTTE Fine Chemical Co., Ltd.